Dr. Siegall Named to Ultragenyx Board of Directors

There are a lot of successful Genetics experts in the U.S.; none more so than Dr. Clay Siegall. Dr. Siegall holds a Ph.D. in Genetics, which he received from George Washington University, and a B.S. in Zoology, which he earned from the University of Maryland. He’s also an avid author of more than 70 publications.

Throughout his career, he has applied for and currently holds, 15 patents. One of his first jobs was at the National Cancer Institute, National Institutes of Health. He worked there for roughly three years, leaving in 1991. From there, he moved on to the Bristol-Myers Squibb Pharmaceutical Research Institute. He spent six years at Bristol-Myers before leaving to start his own company.

A year later, in 1998, Dr. Siegall co-founded Seattle Genetics. He’s currently the company’s President, CEO, and Chairman of the Board of Directors. Siegall was one of the lead researchers that designed an antibody-based cancer therapy called ADCETRIS. In 2011, ADCETRIS was approved by the FDA.

Along with his clinical achievements, Siegall was also in charge of the company’s capital-raising activities. He raised over $675 million through public and private financings. Years later, he was named to the Board of Directors of Alder BioPharmaceuticals.

In 2014, Ultragenyx Pharmaceutical Inc. named Dr. Siegall, Ph.D. to its Board of Directors. Ultragenyx is a biopharmaceutical company that develops treatments and other products for rare and ultra-rare diseases. Also being named to the Board of Directors along with Dr. Siegall is Matthew Fust, former Executive Vice President and CFO of Onyx Pharmaceuticals, Inc.

Eran Nadav, Ph.D., Chairman of the Board of Ultragenyx, expressed the Board’s excitement about Siegall and Fust joining the Board. He believes that they both will be tremendous additions to the company. They have both proven themselves to be leaders in the biopharmaceutical industry countless times.

The decision to bring Dr. Clay Siegall, Ph.D. and Matthew Fust on came after the announcement that Ben Auspitz would be resigning. He was a big part of Ultragenyx for several years and will be missed.

Leave a Reply

Your email address will not be published. Required fields are marked *